Britannia Life Sciences Inc.
BLAB.CN
Get informed when a big investor buys or sells
+ FollowMarket Cap$10.55M
Close$
$-0.00
102.2% downside
Current Fair Value
102.2% downsideOvervalued by 102.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $10.55 Million |
|---|---|
| Enterprise Value | $-1,077,570.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.08 |
| Beta | -0.06 |
| Outstanding Shares | 163,015,179 |
Return
| Return on Equity | 75.01% |
|---|---|
| Return on Assets | 66.59% |
| Return on Invested Capital | -5.08% |
Valuation & Multiples
| P/E Ratio | 0.7 |
|---|---|
| PEG | -0.26 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | -2.65 |
| Enterprise Value to EBIT | 0.95 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | -0.2 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Britannia Life Sciences Inc.
28 employees
CEO: Peter James Shippen Britannia Life Sciences Inc., headquartered in Toronto, Canada, offers specialized services in rigorous product evaluation, comprehensive safety analysis, and adherence to regulatory standards. The company supports businesses within the ...